Aprea Therapeutics
Présence
Aprea Therapeutics est une société cotée sous le symbole boursier APRE (SE).
Dirigeants
Voir l'organigramme avec ses 12 principaux dirigeants
Biographies les plus recherchées chez Aprea Therapeutics
- Oren Gilad, President and Chief Executive Officer
- Christian Schade, Chairman of the Board
- Marc Duey, Director
Changements de dirigeants chez Aprea Therapeutics
- Nadeem Mirza, a rejoint l'entreprise comme Chief Medical Officer (publié le 3 mai 2024).
Créer une alerte
pour suivre les mouvements de dirigeants chez Aprea Therapeutics.
Pharmacie
Aprea Therapeutics a 1 857 concurrents dont Pfizer (Etats—Unis), Johnson & Johnson (Etats—Unis) et Sanofi (France).
Actualités en fusion/acquisition en Pharmacie.
- LakeShore Biopharma changera son nom en LakeShore Biopharma le May 24, 2024. (publié le 25 mai 2024).
- MedMen has filed for bankruptcy protection (publié le 28 avril 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publié le 23 mars 2024).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par Aprea Therapeutics
- Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.com | Aprea Therapeutics
- Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548 | Aprea Therapeutics
- Aprea Therapeutics Appoints Michael A. Kelly to Board of Directors | Aprea Therapeutics
- Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance Changes | Aprea Therapeutics
- Aprea Therapeutics to Present at Upcoming Investor Conferences | Aprea Therapeutics
- Aprea Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on Business Operations | Aprea Therapeutics
- Aprea Therapeutics Announces Expansion of Clinical Trial Evaluating Eprenetapopt for the Front-Line Treatment of TP53 Mutant Acute Myeloid Leukemia (AML) | Aprea Therapeutics
- Aprea Therapeutics Appoints Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to Board of Directors | Aprea Therapeutics
- Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (Eprenetapopt) and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia at the 25th European Hematology Association Annual Meeti
- Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS) | Aprea Therapeutics
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Aprea Therapeutics
- Aprea Therapeutics sur Wikipédia, Google News & Yahoo Finance en 1-click
- Aprea Therapeutics sur LinkedIn, Twitter & YouTube en 1-click
Entrer en contact
Contacter par email ses dirigeants dont Oren Gilad 
Appelez Aprea Therapeutics au +46 85...
